Today, we announced that the FOCUS Phase 3 trial of solriamfetol in adults with ADHD achieved its primary and key secondary endpoints. Learn more here: https://bit.ly/4iGgBoN #ADHD
About us
Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for central nervous system (CNS) conditions that have limited treatment options. Through development of therapeutic options with novel mechanisms of action, we are transforming the approach to treating CNS conditions. At Axsome, we are intensely committed to developing products that meaningfully improve the lives of patients and provide additional therapeutic options for physicians.
- Website
-
http://axsome.com
External link for Axsome Therapeutics, Inc.
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- New York, NY
- Type
- Public Company
- Founded
- 2012
- Specialties
- Biopharmaceuticals, Pain, CNS, Narcolepsy, Major Depressive Disorder, Alzheimer's Disease Agitation, Fibromyalgia, Smoking Cessation, Migraine, and Attention Deficit Hyperactivity Disorder
Locations
-
Primary
Get directions
One World Trade Center
22nd Floor
New York, NY 10007, US
Employees at Axsome Therapeutics, Inc.
Updates
-
The primary endpoint was achieved in the EMERGE Phase 3 trial in migraine patients experiencing inadequate response to oral CGRP inhibitors. Read here to learn more: https://bit.ly/3QwSsog
-
-
Thank you, Brad Loncar and BiotechTV for joining us at One World Trade today to discuss our 2024 accomplishments and our 2025 plans to advance our mission to deliver scientific breakthroughs patients living with serious CNS conditions:
𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: With three approved products and filings for more over the near term, Axsome Therapeutics, Inc.'s CEO Herriot Tabuteau describes the scale and reach this company is building in the CNS space. He updates us on the commercialization of Auvelity and Sunosi, launch plans for the recently approved Symbravo, as well as numerous NDA filings and data readouts that Axsome has coming up over the near term. Plus, how he thinks about business development and the big picture. Full video: https://lnkd.in/gAZSH2pV BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Allucent | NYSE | Klein Hersh | Savills
-
Today we announced positive results from the ENCORE long-term Phase 3 trial of AXS-12 in narcolepsy. Please read the full release for more details: https://bit.ly/3Z5kSJU #narcolepsy
-
-
We are sharing data from across our leading neuroscience pipeline at NEI Congress. Come and meet our team at the posters or at Booths 405, 505, and 897. Learn more about the presentations here: https://bit.ly/48JJHiF #NEIcongress
-
-
We have seven presentations from across our broad portfolio of innovative neuroscience products and product candidates at Psych Congress 2024. Come and meet with us at the conference and learn more about the presentations here: https://bit.ly/3A7mpGZ #PsychCongress2024
-
-
We’re honored to stand with the global narcolepsy community to show support on World Narcolepsy Day. You can learn more about narcolepsy and #WorldNarcolepsyDay here: https://bit.ly/4eB4czN
-
-
This morning we announced that the FDA acknowledged the resubmission of our New Drug Application (NDA) for AXS-07 for the acute treatment of migraine and set a PDUFA action goal date of January 31, 2025. Read more about the news here: https://bit.ly/4gg5Msz
-
-
Come and join a thriving team working to make a meaningful difference in the lives of people affected by hard-to-treat CNS disorders. You can learn about our featured open roles in the video below and see all our open roles here: https://bit.ly/3s2Ykwx #hiring
-
Behavioral symptoms of Alzheimer’s disease, such as agitation, are reported in up to 70% of all patients with Alzheimer’s disease. Learn more about resources available for people with Alzheimer’s and their loved ones here: https://bit.ly/3Xda1yh #AlzheimersAwarenessMonth
-